drugset / Trial / NCT05647330

Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer

NCT05647330

Phase 2 Unknown 55 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of hydroxychloroquine (600mgBID) combined with gemcitabine (1000mg/m2,d1,8) in the third-line and above treatment of advanced NSCLC.

Timeline

Start
2022-12-15
Primary completion
2024-10-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Hydroxychloroquine Small molecule 600 mg Oral

Indications